Transvaginal dehydroepiandrosterone: An unconventional proposal to deliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name: Hormone Precursor Replacement Therapy (HPRT)

Menopause

Volumn 16, Issue 5, 2009, Pages 858-859

  Buster, John E ^a  

^a WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRASTERONE;

CLINICAL TRIAL; EDITORIAL; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; QUALITY OF LIFE; SEXUAL FUNCTION; VAGINA ATROPHY;

ADMINISTRATION, INTRAVAGINAL; ATROPHY; CLINICAL TRIALS, PHASE III AS TOPIC; DEHYDROEPIANDROSTERONE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; VAGINA; ZONA RETICULARIS;

EID: 73349118438     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181ae1fca     Document Type: Editorial

References (7)

1. Labrie F, Archer D, Bouchard C, et al. Serum steroid levels during 12 week intravaginal DHEA administration. Menopause 2009; 16: 897-906.
2. Labrie F, Archer D, Bouchard C, et al,. Intravaginal Prasterone (DHEA), the physiological and highly efficient treatment of vaginal atrophy. Menopause 2009; 16:907-922.
3. Labire F, Archer D, Bouchard C, et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Menopause 2009; 16:923-931.
4. Buster J. Postmenopausal testosterone: time for a reappraisal? Female Patient 2007; 32:22-26.
5. Yildiz B, Goodarzi MO, Guo X, Rotter JI, Azziz R. Heritability of dehydroepiandrosterone sulfate in women with, polycystic ovary syndrome and their sisters. Fertil Steril 2006; 86:1688-1693. (Pubitemid 44778733)
6. Braunstein G. Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies. J Sex Med 2007; 4:859-866. (Pubitemid 47079624)
7. Labrie F. Adrenal androgens and intracrinology. Semin Reprod Med 2004; 22:299-309.